The true incidence of brain metastases (BM) in cancer patients is unknown, but likely exceeds 20-40% depending upon the disease histology. 1 Modern treatments for BM focus on reducing treatment-related adverse effects, maintaining neurocognition, and obtaining durable local control. Historically, whole-brain radiotherapy (WBRT) was 
1. SRS is safe/effective for the treatment of ≤2cm brain metastases. 2. For brain metastases treated with SRS, lesion size and prescribed dose are correlated with rates of local failure and radionecrosis.
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the primary treatment option for BM; however, stereotactic radiosurgery (SRS) is now the preferred approach for patients with a limited number of lesions (up to 3-4) when surgery is not required, and is often considered for patients with a more extensive intracranial burden. [2] [3] [4] Prior studies by the Radiation Therapy Oncology Group (RTOG) determined the maximum tolerated doses for nonbrainstem BM treated with SRS as 24 Gy for tumors 2 cm or less in diameter (maximum tolerated dose not reached), 18 Gy for tumors >2-3 cm, and 15 Gy for tumors >3-4 cm. 5 This dose strategy was subsequently adopted in the RTOG 95-08 phase III trial, testing whether patients with 1-3 lesions treated with WBRT benefited from the addition of SRS. 2 While no overall survival (OS) improvement was observed, local control of individual lesions improved significantly. A subsequent analysis revealed that rates of local control within the 24 Gy, 18 Gy, and 15 Gy cohorts were 85%, 49%, and 45%, respectively, suggesting a steep dose-response gradient, notwithstanding the fact that larger lesions received a smaller dose. 6 Despite the results from RTOG 90-05 5, 7 and 95-08, 8, 9 24 Gy may not be broadly applied as the marginal tumor prescription dose (PD) for BM smaller than 2 cm (small to medium-sized), due to concerns of increased radionecrosis (RN) risk associated with higher PDs (≥21 Gy) and the absence of evidence that higher single fraction doses are required for adequate local control of small tumors. For example, per our institutional protocol, BM smaller than 2 cm are prescribed 21 Gy, except in cases where lesions lie in "eloquent" brain (eg, brainstem, precentral gyrus, visual cortex, Broca's area), for which the prescribed PD is decreased to 15 Gy. This approach aims to optimize the therapeutic index by conferring adequate local control for small tumors while minimizing the risk of significant toxicities (ie, symptomatic RN).
In this study, we analyzed data from a prospective patient registry to determine if PD (≤15 Gy vs ≥21 Gy) correlated with the incidences of local failure (LF) or RN for all BM ≤2 cm.
Materials and Methods
After obtaining institutional ethics board approval, a prospective registry of BM patients treated at our institution between 2008 and 2017 was queried. We included all patients 18 years or older who received Gamma Knife SRS for BM smaller than 2 cm with MRI imaging follow-up. For all patients included in our registry, informed consent was obtained during patients' initial consultation.
Stereotactic Radiosurgery
Patients were treated using the Gamma Knife 4C or Perfexion radiosurgery unit (Elekta AB). Using GammaPlan (Elekta AB), patient MRIs (gadolinium-enhanced T1-weighted and T2-weighted imaging sequences) and CTs were utilized for target and organ-at-risk delineation, SRS planning, and dosimetric characterization. All patients received single fraction SRS prescribed to a median isodose line of 50% (range 30-90; 88% [1350 lesions] were prescribed to an isodose ranging 40-60%), with gross tumor volume coverage >98%. Lesions in the prefrontal, primary motor, limbic, visual, or primary somatosensory cortex, Wernicke's or Broca's area, or brainstem were prescribed 15 Gy per physician discretion, while tumors in "non eloquent" brain were prescribed ≥21 Gy. All radiosurgery plans were assessed, evaluated, and approved by 2 physicists, a radiation oncologist, and a neurosurgeon. Standard terminology was adopted when reporting Gamma Knife SRS treatment parameters. 10 Our current institutional practice regarding SRS is as follows: (1) patients with fewer than 10 BM and a good performance status (PS) are treated with SRS alone; (2) patients with less than 10 BM but poor PS, who are not fit for SRS, are treated with WBRT or supportive care alone; (3) patients with more than 10 BM receive WBRT or supportive care alone. Of note, some patients in the study were treated with WBRT in conjunction with SRS. In most cases, this was performed in a previous era, during which our standard of care was to use SRS as a planned boost to WBRT. In other instances, patients had previously been treated with WBRT and later required salvage SRS for new or progressive lesions.
After radiosurgery, all patients were followed in our multidisciplinary brain metastases clinic. Contrast-enhanced MRI and clinical follow-up exams were performed every 3 months unless earlier imaging or clinical assessments were indicated. In addition, prior to each clinical appointment, imaging was evaluated during a weekly multidisciplinary conference to assess treatment response (LF and RN events), and data were entered into the prospective registry database. Data regarding adverse events were also obtained at 3-month intervals, or more frequently, if clinically warranted.
Outcomes
Outcomes were measured from the date of SRS. Whole brain radiotherapy was considered a censoring event and death a competing risk for LF and RN. Patient management decisions, including consensus determinations of LF
Importance of the study
We evaluated the impact of SRS PD (≤15 Gy vs ≥21 Gy) on LF and RN for brain metastasis ≤2 cm in greatest diameter. We show that for tumors ≤1 cm, when comparing PD ≤15 Gy with ≥21 Gy, the risks of LF and RN are equivalent. However, for lesions >1 cm, PD ≥21 Gy is associated with a lower incidence of LF without significantly increasing the risk of RN. Overall, we show that SRS is associated with a low rate of toxicity and that local control is excellent in the modern era, especially for lesions ≤1 cm.
versus RN, were made during the weekly multidisciplinary care conference attended by radiation oncologists, neurosurgeons, and physicists.
In cases where it was unclear whether or not changes to the treated tumor represented LF versus RN, short-interval follow-up imaging was performed and MRI perfusion sequences were utilized when available. If a consensus was still not reached, and the patient continued to be symptomatic after a week or more of steroids, surgical resection was recommended.
Local failure was defined as an increase in maximum tumor diameter or volume >10% on consecutive brain images (MRI). 11 Brain metastases that were unchanged or smaller on follow-up MRI were considered controlled. Radionecrosis was determined on the basis of MRI perfusion or defined as non-nodular tumor growth (including edema) that improved with steroids and became stable or smaller on follow-up MRI. 12 Back-dating was not used. The dates for events (LF and RN) used in our analysis correspond to the exact date that the corresponding determination was made clinically.
We assessed whether the following variables were associated with LF or RN:
• 
Statistical Analysis
Categorical variables were summarized with counts and percentages. Continuous variables were summarized with medians and/or ranges. Cumulative incidence of LF and RN was calculated using Fine and Grey's competing event analysis with death as the competing event. Cox regression modeling of subhazard distribution on events of interest was performed for univariate and multivariate analyses, while death was the competing event. Wholebrain radiotherapy was a censoring event for all per-lesion analyses. Overall survival (OS) was estimated using the Kaplan-Meier product-limit method. All P-values were 2-sided; P < 0.05 was used to determine statistical significance. Risks were calculated as hazard ratios (HRs), with 95% confidence intervals (CIs). Statistical analyses were performed using version 9.4 of the SAS system for Windows (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) .
Results
We assessed 1762 prospectively registered patients treated between January 1, 2008 and February 1, 2017 (Supplementary Figure 1 , study flow chart, online only). Ultimately, 535 patients (1533 discrete BM) met the study criteria. Patient and lesion characteristics are presented in Tables 1 and 2 The 2-year incidence of LF was lower for the PD ≥21 Gy (9.34%; 95% CI: 5.97-12.71) compared with the PD ≤15 Gy (19.53%; 95% CI: 10.80-28.27) (subHR 2.32; 95% CI: 1.43 3.77; P = 0.0006; Fig. 1A ). The 2-year incidence of RN was not significantly higher for the group treated with PD ≥21 Gy (9.48%; 95% CI: 6.38-12.58) compared with the PD ≤15 Gy group (7.47%; 95% CI: 1.86-13.07) (subHR 0.63; 95% CI: 0.34-1.20; P = 0.16; Fig. 1B ).
With respect to increased LF rates, univariate as well as multivariate analyses (Table 3, Supplementary Table 7 for SRS treatment parameter analysis) identified PD (≤15 Gy), tumor size (>1 cm) (Fig. 1C) , and the absence of pre-SRS WBRT as significant correlates, while histology, number of lesions treated, extracranial disease status, ECOG, and previous uses of systemic therapy or immunotherapy were not. With respect to increased rates of RN, univariate and multivariate analyses (Table 4, Supplementary Table 8 for SRS parameters analysis) demonstrated that tumor size (>1 cm) (Fig. 1D ) and use of steroids at the time of SRS were significant correlates. Prescription dose, primary tumor histology, number of treated lesions, extracranial disease status, ECOG, previous uses of systemic therapy or immunotherapy, and pre-SRS WBRT were not significantly correlated.
Due to the correlation between tumor size and the incidences of LF and RN, we performed a subgroup analysis of tumors ≤1 cm versus those >1 cm. For BM ≤1 cm (Supplementary Table 3 ), pre-SRS WBRT was associated with a reduced incidence of LF (subHR 0.316; 95% CI: 0.154-0.648; P-value = 0.0017), whereas PD ( Fig. 2A) , histology, number of lesions treated, extracranial disease status, ECOG, previous uses of systemic therapy or
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immunotherapy, and previous steroid use did not correlate. For RN in BM ≤1 cm, tumor histology (radiosensitive) correlated with a lower risk (subHR 0.236; 95% CI: 0.096-0.576; P = 0.0015), whereas no correlations were identified for PD (Fig. 2B) , primary tumor site, number of lesions at SRS, extracranial disease status, ECOG, previous uses of systemic therapy or immunotherapy, pre-SRS WBRT, or steroid use. For BM >1 cm but ≤2 cm (Supplementary Table 4) , PD ≤15 Gy (subHR 3.171; 95% CI: 1.838-5.469; P < 0.0001; Fig. 2C ) correlated with an increased risk of LF, whereas no correlation was identified between the incidence of LF and histology, number of lesions treated, extracranial disease status, ECOG, previous uses of systemic therapy or immunotherapy, pre-SRS WBRT, or steroid use. For BM >1 cm but ≤2 cm, none of the tested variables, including marginal PD (Fig. 2D) , correlated with RN, except for steroid use at the time of SRS treatment.
To investigate the influence of previous WBRT or WBRT used in combination with SRS (SRS boost), we performed a subgroup analysis of lesions not treated previously or concurrently with WBRT. Of 900 such lesions, 270 received PD ≤15 Gy and 630 received PD ≥21 Gy. The majority (617 [68%]) were ≤1 cm. Among the 900 lesions, no significant differences were observed in 1-and 2-year cumulative incidences of LF and RN according to PD (≤15 Gy vs ≥21 Gy) (Supplementary Figure 2A and 2B and Supplementary  Table 5 ). An analysis based on tumor size (Supplementary Table 6 ) revealed higher incidences of LF (Supplementary Figure 2C ; P < 0.001) and RN (Supplementary Figure 2D ; P < 0001) in BM >1 cm but ≤2 cm. For BM ≤1 cm, cumulative incidences of LF and RN were not correlated to PD; however, for lesions >1 cm but ≤2 cm, the incidence of LF was significantly higher for lesions treated with ≤15 Gy (30.73%; 95% CI: 6.81-54.64) compared with lesions treated with ≥21 Gy (12.22%; 95% CI: 3.65-20.79) (subHR 2.52; 95% CI: 1.18-5.37; P = 0.0175; Supplementary Figure 2E) , whereas the incidence of RN was not significantly (P = 0.47) different for lesions >1 cm but ≤2 cm according to PD (Supplementary Figure 2F) . Thus, these results are nearly identical to the findings from the larger group. We performed additional Figure 3A-F) to assess the effect of prescription isodose. We evaluated all lesions treated with a prescription isodose of 50% ± 5% (and no previous or concurrent WBRT), which again yielded results similar to that of the overall cohort.
NeuroOncology analyses (Supplementary Tables 9-11 and
Finally, as duration of follow-up is important to the outcomes of interest in this study, we performed an analysis of lesions treated with SRS alone (no previous or combination WBRT) and imaging follow-up ≥6 months. Of 730 lesions meeting these criteria, 198 received PD ≤15 Gy and 532 received PD ≥21 Gy. Results of this separate analysis are shown in Supplementary Tables 12-14 ; however, the pattern of outcomes was identical to the results from the larger group.
Discussion
According to the results of 2 seminal RTOG studies, small to medium-sized (<2 cm) BM can be safely and effectively treated with an SRS PD of 24 Gy. In this study, we sought to determine the risk-benefit ratio (RN:LF) for a lower PD (≤15 Gy compared with ≥21 Gy) for tumors in eloquent brain. According to the linear quadratic model, for late toxicities such as RN, a single fraction PD of 21 Gy has a relatively higher biological equivalent dose (BED) 3 .0 of 168.0, compared with BED 3.0 = 90.0 for 15 Gy (a 1.85-fold difference), than would be suggested by a purely linear comparison of these doses (1.4-fold). Biological equivalent dose indicates, quantitatively, the effect of radiotherapy treatment on both tumor (typically BED 10 ) and normal tissues (typically BED 3 ), taking into account changes in dose-per-fraction, total dose, and overall treatment time. 16 This rationale was the basis for our institution's practice, prior to this analysis, of prescribing 15 Gy for small to medium-sized lesions located in eloquent areas despite evidence that higher doses are likely to be safe and associated with higher rates of local control.
Our results complement previously published studies describing the effects of dose and tumor size on SRS outcomes for small to medium-sized BM (≤2 cm). One-and 2-year actuarial local control rates were 86% and 78%, respectively, for lesions ≤1 cm, compared with 56% and 24%, respectively, for lesions larger than 1 cm (P = 0.0016). The authors' conclusion was that a maximum tumor diameter of 1 cm represents a clinically relevant cutoff for LF, which was subsequently validated by several groups. 6, [18] [19] [20] [21] We have now validated that finding in a larger cohort with long-term follow-up. Thus, based on our work in conjunction with prior studies, one might conclude that PD for small-sized BM (≤1 cm) does not significantly influence rates of LF or RN, whereas for lesions >1 cm, PD strongly influences the likelihood of LF without significantly altering the risk of RN. However, caution should be used when applying these data to clinical decision making. For example, in regard to RN risk, these results may only be applicable to eloquent brain, which may be differentially sensitive to RN compared with noneloquent brain. 22 Furthermore, despite our findings, our institutional practice has been and remains to treat all brainstem lesions with PD 15 Gy, regardless of size, due to concern for catastrophic RN. In the study by Mohammadi et al, 896 patients with 3034 BM ≤2 cm were treated with Gamma Knife SRS with or without WBRT (38%); PD was 24 Gy for 2410 tumors (80%), 19-23 Gy for 408 tumors (13%), and 15-18 Gy for 216 tumors (7%). 18 With 6.2 months of median follow-up, PD 24 Gy to the median isodose line of 56% resulted in significantly decreased rates of LF compared with lower doses (15) (16) (17) (18) (19) (20) (21) (22) (23) . Multivariate analysis showed that lesion size >1 cm (P < 0.001), PD <24 Gy (P = 0.01), and no additional radiation (WBRT) (P = 0.001) were independently associated with higher rates of LF. Nonetheless, the cumulative incidences of LF were ~4% versus ~5% for PD 24 Gy and <24 Gy, and RN incidences were ~8.5% (PD 24 Gy) and ~6.5% (PD < 24 Gy), which are small absolute differences. In addition, caution should be taken when interpreting Mohammadi et al results due to the potential impact of WBRT and the short median duration of imaging follow-up, which makes a true assessment of LF and RN definition difficult, as RN and LF events usually occur 9-12 months after SRS. 20, [23] [24] [25] In our study, we analyzed a larger cohort with longer imaging follow-up, and found that pre-WBRT was associated with a lower rate of LF. This is likely due to the fact that the majority of patients received WBRT in combination with SRS (previously the standard of care), meaning that a higher radiation dose was delivered to targeted lesions. Of note, pre-SRS WBRT did not correlate with the rate of RN in our cohort.
Prior publications have described potential correlates for the diagnosis of RN 26, 27 and factors associated with an increased 
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risk of RN included PD, fraction size, concurrent chemotherapy, V10 Gy, and V12 Gy. 20, 28, 29 We report that tumor size (>1 cm), and steroid use at the time of SRS (which likely reflects the presence of symptomatic edema at the time of treatment) were significantly associated with an increased risk of RN. However, our univariate analysis for lesions >1 cm did not reveal associations with RN for the tested variables. Our observation that radioresistant histology correlated with RN may reflect prior treatment with multiple lines of systemic therapy or tumor biology. Prior steroid use may identify patients whose brain parenchyma has an intrinsic inflammatory phenotype and are more sensitive to an SRS related inflammatory response. We also found on univariate analysis that previous use of immunotherapy was not correlated to RN risk. This finding should be validated prospectively, as RN is known to be due, in part, to an immune reaction, and immunotherapy agents have the ability to inhibit pathways that maintain self-tolerance to prevent autoimmunity. 30 The significance of our results is limited because it represents a single institution and single modality (Gamma Knife) experience, based on a retrospective analysis of a prospectively maintained registry. Moreover, all SRS studies are hampered by the inability to conclusively differentiate RN from LF, unless lesions are surgically resected, and the potential partial overlap of these pathologic entities. However, our determinations were based on multidisciplinary consensus, and account for the temporal evolution of the lesions during MRI-and clinically based follow-up to determine the most likely entity. Another valid criticism is that we may not have the statistical power necessary to identify a dose response for LF in radioresistant histologies such as melanoma and gastrointestinal cancers or to define a dose response for RN in patients treated with immunotherapy; therefore our conclusions should be interpreted with caution, particularly in those clinical scenarios.
Conclusion
Our results suggest that BM size and PD strongly and independently correlate with LF and RN. Overall, in our analysis, for BM ≤1 cm, PD ≤15 Gy incurs a similar risk of LF and RN compared with ≥21 Gy, and either dose may be considered for lesions in eloquent brain. However, for BM >1 cm but ≤2 cm, ≤15 Gy was associated with a higher incidence of local failure rates compared with ≥21 Gy, without a corresponding significantly decreased risk of RN. However, we suggest that caution be applied when incorporating these data into clinical decision making. Specifically, within the brainstem, we do not recommend increasing the prescription dose to 21 Gy for tumors of any size given the catastrophic nature of RN when it occurs at this site.
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